探討紅麴二次代謝產物 monascin 和 ankaflavin對非酒精性脂肪肝之調控

Effects of the Monascus secondary polyketide metabolites, monascin and ankaflavin on regulation of nonalcoholic fatty liver disease

陳庭宏(Ting-Hung Chen)

指導教授 ： 潘子明

國立臺灣大學/生命科學院/生化科技學系/碩士(2012年)

https://doi.org/10.6342/NTU.2012.10204

摘要

無資料

關鍵字

脂肪變性肝炎 ； 非酒精性脂肪肝 ； 紅麴黃色素 ； monascin ； ankaflavin

並列摘要

After the control of hepatitis viruses and westernization of the lifestyle in Taiwan, an increasing burden of nonalcoholic fatty liver disease (NAFLD) is anticipated and active prophylactic measures should be implemented. NAFLD is a clinicopathological term that encompasses a spectrum of abnormalities ranging from simple triglyceride accumulation in the hepatocytes to hepatic steatosis with inflammation, also known as nonalcoholic steatohepatitis (NASH). NASH can also progress to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma. Recently, there are many types of medicines that are introduced to improve NAFLD, but none of them are specific for preventing or treating NAFLD in full aspects. The hypolipidemic and anti-inflammation effects of monascin (MS) and ankaflavin (AK) may indicate that they have potential to prevent or treat NAFLD. In the present study, we examined the oleic acid-induced steatosis effect in FL83B cell line treated with MS and AK. In vivo, the mice were fed with high-fat diet for NAFLD induction. Results showed that MS and AK reduced the steatosis effect in vitro and in vivo, and both in preventive and therapeutic models. Moreover, we discovered for the first time that the hypolipidemic effect of MS and AK may be achieved by sterol regulatory element binding protein and peroxisome proliferator-activated receptor alpha-related lipogenesis and fatty-acid oxidation pathways. Furthermore, MS and AK reduce the inflammatory cytokines in the liver tissue, which indicates that the metabolites may improve NAFLD by their hypolipidemic and anti-inflammation effects.

並列關鍵字

nonalcoholic steatohepatitis (NASH) ； nonalcoholic fatty liver disease (NAFLD) ； monascin (MS) ； ankaflavin (AK)

參考文獻

Park, H. G., Stamenova, E. K., Jong, S. C. 2004. Phylogenetic relationships of monascus species inferred from the its and the partial beta-tubulin gene. Bot Bull Acad Sinica. 45: 325-330.

Abbate, S. L., Brunzell, J. D. 1990. Pathophysiology of hyperlipidemia in diabetes mellitus. J Cardiovasc Pharmacol. 16 Suppl 9: S1-7.

Abdelmalek, M. F., Angulo, P., Jorgensen, R. A., Sylvestre, P. B., Lindor, K. D. 2001. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. American Journal of Gastroenterology. 96: 2711-2717.

Akihisa, T., Tokuda, H., Ukiya, M., Kiyota, A., Yasukawa, K., Sakamoto, N., Kimura, Y., Suzuki, T., Takayasu, J., Nishino, H. 2005. Anti-tumor-initiating effects of monascin, an azaphilonoid pigment from the extract of monascus pilosus fermented rice (red-mold rice). Chem Biodivers. 2: 1305-1309.

Aniya, Y., Ohtani, II, Higa, T., Miyagi, C., Gibo, H., Shimabukuro, M., Nakanishi, H., Taira, J. 2000. Dimerumic acid as an antioxidant of the mold, monascus anka. Free Radic Biol Med. 28: 999-1004.